3月10日，Ars Pharmaceuticals, Inc.（SPRY.US）公布财报，公告显示公司2025财年净利润为-1.71亿美元，同比减少2237.50%；其中营业收入为84.28百万美元，同比减少5.46%，每股基本收益为-1.74美元。从资产负债表来看，Ars Pharmaceuticals, Inc.（SPRY.US）总负债2.13亿美元，其中短期债务588000.00美元，...
Source Link3月10日，Ars Pharmaceuticals, Inc.（SPRY.US）公布财报，公告显示公司2025财年净利润为-1.71亿美元，同比减少2237.50%；其中营业收入为84.28百万美元，同比减少5.46%，每股基本收益为-1.74美元。从资产负债表来看，Ars Pharmaceuticals, Inc.（SPRY.US）总负债2.13亿美元，其中短期债务588000.00美元，...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.